For patients suffering a heart attack requiring emergency stenting, the standard practice of combining aspirin with a second blood thinner for a full year carries meaningful bleeding risk — a tradeoff that cardiologists have long sought to minimize. A newly designed large randomized trial could fundamentally shift how antiplatelet therapy is initiated from the very moment of intervention, rather than dropped down weeks or months later.
The PREMIUM trial is enrolling 2,268 STEMI patients undergoing primary PCI with contemporary platinum-chromium everolimus-eluting stents. Participants are randomized 1:1 to either upfront prasugrel monotherapy — beginning before the procedure with a 20 mg loading dose followed by 3.75 mg daily — or the conventional 12-month dual antiplatelet therapy (DAPT) combining aspirin plus prasugrel. The primary endpoint is a noninferiority composite of all-cause death, myocardial infarction, and stroke at 12 months, while the key secondary endpoint tests for superiority in reducing BARC type 3 or 5 bleeding events.
What distinguishes PREMIUM from its predecessors is its ambition to eliminate aspirin from the very outset, rather than after an initial DAPT window. Prior landmark trials — including TWILIGHT and STOPDAPT-2 — demonstrated that de-escalating to P2Y12 monotherapy after one to three months of DAPT was safe in broader acute coronary syndrome populations. STEMI patients, however, represent a higher-thrombotic-risk subgroup where immediate aspirin omission has not been rigorously tested. The use of intravascular imaging guidance throughout — a practice associated with better stent deployment and lower ischemic event rates — is a meaningful methodological strength that improves both internal and external validity. As an open-label design, observer bias in softer endpoints remains a limitation. Results will be closely watched, as a positive noninferiority outcome could simplify post-STEMI antithrombotic regimens significantly and reduce gastrointestinal and hemorrhagic complications in a population already burdened by acute illness.